Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023 Apr 24, 2023
Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office Apr 11, 2023
Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial Apr 5, 2023
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023 Feb 7, 2023
